Biomedical reports最新文献

Early detection of cardiac impairment and prediction of right ventricular hypertrophy in patients with connective tissue disease. 结缔组织病患者心脏损害的早期检测及右心室肥厚的预测。

IF 2.3

Biomedical reports Pub Date : 2025-03-27 eCollection Date: 2025-05-01 DOI: 10.3892/br.2025.1970

Jiayan Shen, Guangrong Xiao, Shuqing Fang, Haohao Yang, Zheren Zhao, Yun Xu, Meng Jiang, Song Zhong

{"title":"Early detection of cardiac impairment and prediction of right ventricular hypertrophy in patients with connective tissue disease.","authors":"Jiayan Shen, Guangrong Xiao, Shuqing Fang, Haohao Yang, Zheren Zhao, Yun Xu, Meng Jiang, Song Zhong","doi":"10.3892/br.2025.1970","DOIUrl":"https://doi.org/10.3892/br.2025.1970","url":null,"abstract":"Progressive right ventricle (RV) failure and death in connective tissue disease (CTD) are related to RV hypertrophy (RVH) and dilation, irrespective of pulmonary arterial hypertension (PAH). Therefore, detecting cardiac impairment before RVH and determining RVH predictors is crucial for timely intervention. The present prospective cohort study aimed to identify cardiac markers that occur before RVH and to investigate predictors of RVH. CTD was diagnosed based on clinical features, laboratory findings and imaging data. The cardiac functions of patients with CTD were evaluated using echocardiography, cardiovascular magnetic resonance (CMR) and multi-modality cardiac imaging studies, including RV wall thickness, systolic functions, late gadolinium enhancement, T1 maps and biventricular strain analysis. A total of 52 patients with CTD with non-right ventricular hypertrophy (non-RVH), 34 patients with RVH and 50 healthy individuals were prospectively included. The impaired cardiac indices in patients with RVH included RV ejection fraction, ventricular dimensions, global myocardial deformation, late gadolinium enhancement and ventricular extracellular volume (ECV). The cardiac death rate did not differ significantly between the RVH and non-RVH groups (P=0.14). Conventional parameters, including serum cardiac markers and the left ventricular ejection fraction, showed no significant changes in the non-RVH group compared with the control group. Regarding fibrosis assessment using CMR, an elevated native T1 value (1,362±72 msec in the non-RVH group vs. 1,268±42 in the control group; P<0.001) and ECV (31±4% in the non-RVH group vs. 25±3% in the control group; P<0.001) were observed. By contrast, T1 myocardium/msec 15 min post-contrast of the left ventricle in the RVH group was significantly decreased compared with that in the non-RVH group, indicating an increase in the extracellular matrix at this stage. RVH was predicted by pulmonary arterial pressure (PAP) in patients in the non-RVH group (t-statistic, 2.84; P=0.01), whereas after RVH presentation, RV end-systolic volume (RVESV) became a progression predictor of RVH (t-statistic, 7.98; P<0.0001). No other cardiac imaging or laboratory findings predicted RVH. To the best of our knowledge, the present study was the first to highlight the non-invasive detection of cardiac tissue impairment using CMR and provide support for cardiac treatment initiation before RVH detection. The predictors of RVH vary with the heart disease stage. PAP in the non-RVH stage and incompetence of RVESV in the RVH stage predicted the progression of RVH. The present study was part of a clinical trial (NCT03271385), which was registered on July 1, 2017, and started on September 1, 2017.","PeriodicalId":8863,"journal":{"name":"Biomedical reports","volume":"22 5","pages":"92"},"PeriodicalIF":2.3,"publicationDate":"2025-03-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11995382/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143963944","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Gallein increases prostaglandin F2α‑induced osteoprotegerin and IL‑6 secretion in osteoblasts. galgalin增加前列腺素F2α诱导的骨保护素和成骨细胞IL - 6的分泌。

IF 2.3

Biomedical reports Pub Date : 2024-08-14 eCollection Date: 2024-11-01 DOI: 10.3892/br.2024.1835

Gen Kuroyanagi, Tomoyuki Hioki, Rie Matsushima-Nishiwaki, Takuya Omura, Osamu Kozawa, Haruhiko Tokuda

{"title":"Gallein increases prostaglandin F2α‑induced osteoprotegerin and IL‑6 secretion in osteoblasts.","authors":"Gen Kuroyanagi, Tomoyuki Hioki, Rie Matsushima-Nishiwaki, Takuya Omura, Osamu Kozawa, Haruhiko Tokuda","doi":"10.3892/br.2024.1835","DOIUrl":"10.3892/br.2024.1835","url":null,"abstract":"Gallein is a known Gβγ subunit inhibitor, but its function in bone metabolism, especially in osteoblasts, and its molecular mechanism remains to be elucidated. Osteoprotegerin (OPG), which is secreted from osteoblasts, binds to nuclear factor kB receptor activator (RANK) ligand (RANKL) as a decoy receptor, prevents RANKL-RANK binding, and inhibits bone resorption. IL-6 is not only a bone resorption factor but also as a bone metabolism regulator. Prostaglandin F2α (PGF2α) promotes p44/p42 MAPK, p38 MAPK and stress-activated protein kinase/JNK phosphorylation in osteoblast-like MC3T3-E1 cells. In MC3T3-E1 cells, activated p44/p42 and p38 MAPKs promote IL-6 secretion and activated p44/p42 and p38 MAPKs and JNK promote OPG secretion. The present study aimed to investigate the effect and mechanism of gallein on PGF2α-induced OPG and IL-6 secretion using an osteoblastic MC3T3-E1 cell line. It was found that gallein significantly increased PGF2α-induced OPG and IL-6 secretion in the MC3T3-E1 cell. By contrast, fluorescein, which is a gallein-like compound that does not bind to Gβγ, did not affect PGF2α-induced OPG and IL-6 secretion. Gallein significantly improved the PGF2α-induced OPG and IL-6 mRNA expression levels. Gallein did not affect the PGF2α-activated phosphorylation of p44/p42 and p38 MAPKs and JNK. Gallein increased PGF2α-induced OPG and IL-6 secretion in osteoblasts, indicating that gallein may regulate bone remodeling via OPG/IL-6 in bone metabolism.","PeriodicalId":8863,"journal":{"name":"Biomedical reports","volume":"21 5","pages":"147"},"PeriodicalIF":2.3,"publicationDate":"2024-08-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11618980/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142783970","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Anti‑angiogenic and cytotoxic evaluation of green‑synthesized Fe2ZnO4 nanoparticles against MCF‑7 cell line 绿色合成的 Fe2ZnO4 纳米粒子对 MCF-7 细胞系的抗血管生成和细胞毒性评估

IF 2.3

Biomedical reports Pub Date : 2024-01-10 DOI: 10.3892/br.2024.1724

Asma' Al‑Zabin, Tuqa Abu Thiab, M. Zihlif, A. Al-Hunaiti, Hamzeh J. Al-Ameer, W. Al-Awaida, Amer Imraish